ArticleDrug delivery and translational research2026
Tabletting of single-screw hot melt extruded itraconazole: HPMC-AS amorphous solid dispersion by 3D printing and direct compression.
Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated the development of high drug loading amorphous solid dispersions (ASDs) of itraconazole (ITZ) using single screw hot melt extrusion (HME) for fused deposition modelling (FDM) 3D printing (3DP). ITZ ASDs containing 20-22% w/w ITZ were prepared with Hydroxypropyl methylcellulose acetate succinate, medium grade, medium particle (HPMCAS-MMP) and processed into filaments for 3DP, while a conventional direct compression ASD was produced as a benchmark to assess the influence of manufacturing method on drug release. While both dosage forms were based on the same ASD system, the final tablet compositions differed due to the requirements of each manufacturing method. Solid-state characterisation using differential scanning calorimetry (DSC) and powder X-ray diffraction (PXRD) confirmed the amorphous nature of the formulations. Dissolution studies were conducted in phosphate buffer saline (PBS, pH 7.4). The direct compressed ASD tablets showed rapid drug release (~ 63% in 30 min) while much slower release was observed for the 3D printed tablets. At 30 min F1 (10% triethyl citrate (TEC)) released only 3% and F2 (12.5% TEC) released 6%. This behaviour may be attributed to the printed tablet's dense structure, buoyancy, and formation of a viscous hydrogel barrier at the surface. This study shows that single screw HME can be used to produce ITZ ASDs for both 3DP and conventional tabletting, while also demonstrating that the dense microstructure of 3D printed tablets limits their ability to achieve an immediate release profile. Further optimisation of formulation and tablet design, such as infill will be needed to improve release performance. These findings provide a basis for future formulation and design strategies to enhance the performance of 3D printed dosage forms.
Indexed as
Identifiers
42081178What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.